研究者情報

マスター

アカウント（マスター）

• 氏名

  水野　雄貴(ミズノ　ユウキ), ミズノ　ユウキ

所属（マスター）

• アイソトープ総合センター

所属（マスター）

• アイソトープ総合センター

独自項目

syllabus

• 2021, 医理工連携放射線防護学, Radiation Protection for Biomedical Science and Engineering, 修士課程, 医理工学院, 放射線防護、国際的基準、国内法令、被ばく線量、リスク、安全取扱 Radiation Protection, International Standard, National Law, Exposed Dose, Risk, Safe Handling
• 2021, 分子プローブ学, Molecular Probe Science, 修士課程, 医理工学院, 分子プローブ、核医学診断用（PET、SPECT）分子プローブ、核医学治療用分子プローブ、放射性同位元素の製造、標識反応、自動合成装置 Molecular Probe, Nuclear Medicine imaging (PET, SPECT) Probe, Nuclear Medicine therapy Probe, Production of Radioisotope, Radiolabeling Reaction, Automated Synthetic Apparatus,
• 2021, 総合医理工学研究Ⅰ, General Research on Biomedical Science and Engineering I, 修士課程, 医理工学院, 分子プローブ、機能分子探索、ラジオセラノスティクス、プローブ合成・合成装置、病態分析、トランスレーション
• 2021, 総合医理工学研究Ⅱ, General Research on Biomedical Science and Engineering II, 修士課程, 医理工学院, 分子プローブ、機能分子探索、ラジオセラノスティクス、プローブ合成・合成装置、病態分析、トランスレーション
• 2021, 先端医理工学研究Ⅰ, Advanced Research on Biomedical Science and Engineering I, 博士後期課程, 医理工学院, 分子プローブ、機能分子探索、ラジオセラノスティクス、プローブ合成・合成装置、病態分析、トランスレーション
• 2021, 先端医理工学研究Ⅱ, Advanced Research on Biomedical Science and Engineering II, 博士後期課程, 医理工学院, 分子プローブ、機能分子探索、ラジオセラノスティクス、プローブ合成・合成装置、病態分析、トランスレーション

researchmap

プロフィール情報

学位

• 博士 (薬科学)（2017年03月 千葉大学）

プロフィール情報

• 姓

  水野, ミズノ

• 名

  雄貴, ユウキ

• ID各種

  201801014214058587

業績リスト

研究キーワード

• ペプチド   多価効果   放射性医薬品   

研究分野

• ライフサイエンス / 放射線科学
• ライフサイエンス / 薬系分析、物理化学

経歴

• 2020年04月 - 現在 北海道大学 アイソトープ総合センター 助教
• 2017年04月 - 2020年03月 昭和薬科大学 薬品物理化学研究室 特任助教
• 2014年04月 - 2017年03月 日本学術振興会 特別研究員

学歴

• 2014年04月 - 2017年03月   千葉大学大学院   医学薬学府   先端創薬科学専攻博士課程
• 2012年04月 - 2014年03月   千葉大学大学院   医学薬学府   総合薬品科学専攻修士課程
• 2008年04月 - 2012年03月   千葉大学   薬学部   薬科学科

受賞

• 2023年09月 第6回放射性薬品科学研究会 若手研究者部門 優秀発表賞
   複数のintegrin αvβ3と同時結合可能な多価cRGDペプチドの開発と多様な放射性同位元素で標識可能な構造への展開 

  受賞者: 水野雄貴
• 2015年03月 日本薬学会 日本薬学会第135年会優秀発表賞
   

  受賞者: 水野 雄貴
• 2014年05月 日本分子イメージング学会 最優秀発表賞
   

  受賞者: 水野 雄貴
• 2012年08月 物理系薬学部会 若手研究者奨励賞
   

  受賞者: 水野 雄貴

論文

• Thymidine Phosphorylase Imaging Probe for Differential Diagnosis of Metabolic dysfunction-associated Steatohepatitis.

  Kei Higashikawa, Riho Uehara, Sawako Horiguchi, Yuki Shibata, Naoto Okubo, Yuki Mizuno, Hironobu Yasui, Shunsuke Ohnishi, Hiroshi Takeda, Yuji Kuge

  Molecular imaging and biology 2024年11月13日 

  PURPOSE: Metabolic dysfunction-associated steatotic liver disease (MASLD) comprises simple steatosis (SS), which has a low risk of mortality, and metabolic dysfunction-associated steatohepatitis (MASH), which can progress to liver cirrhosis and hepatocellular carcinoma. Because differentiation between MASH and SS is the most important issue in the diagnosis of MASLD, the establishment of noninvasive diagnostic methods is urgently needed. In this study, we evaluated the potential of [123I]IIMU, a thymidine phosphorylase (TYMP) targeted SPECT imaging probe, for differential diagnosis of MASLD in a preclinical animal model. PROCEDURES: SS and MASH mice were prepared by feeding db/db mice with a standard diet and a methionine/choline-deficient diet, respectively. Control mice were prepared by feeding m/m mice with a standard diet. TYMP expression in the liver was evaluated by RT-PCR, western blotting, and immunohistochemistry. The biodistribution of [125I]IIMU in the three model mice was evaluated at 30 min post-injection. SPECT/CT imaging studies of the three model mice were performed 30 min after injection of [123I]IIMU. RESULTS: Hepatic TYMP expression level was the highest in the SS mice and the lowest in the MASH mice at both mRNA and protein levels. The immunohistochemistry experiment showed a patchy distribution of TYMP only in the liver of MASH mice. In the biodistribution study, the hepatic accumulation of [125I]IIMU was the highest in the SS mice and the lowest in the MASH mice. The SPECT/CT imaging study showed similar results to the biodistribution experiment. CONCLUSION: Hepatic TYMP expression level may serve as a promising imaging biomarker for differential diagnosis of SS and MASH. SPECT imaging using [123I]IIMU potentially provides a novel noninvasive diagnostic method to differentiate MASH and SS.
• Feasibility study of multimodal imaging for redox status and glucose metabolism in tumor.

  Kazuhiro Kato, Hironobu Yasui, Hideo Sato-Akaba, Miho C Emoto, Hirotada G Fujii, Maciej M Kmiec, Periannan Kuppusamy, Yuki Mizuno, Yuji Kuge, Masaki Nagane, Tadashi Yamashita, Osamu Inanami

  Free radical biology & medicine 2024年04月02日 

  Understanding the tumor redox status is important for efficient cancer treatment. Here, we noninvasively detected changes in the redox environment of tumors before and after cancer treatment in the same individuals using a novel compact and portable electron paramagnetic resonance imaging (EPRI) device and compared the results with glycolytic information obtained through autoradiography using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG). Human colon cancer HCT116 xenografts were used in the mice. We used 3-carbamoyl-PROXYL (3CP) as a paramagnetic and redox status probe for the EPRI of tumors. The first EPRI was followed by the intraperitoneal administration of buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis, or X-ray irradiation of the tumor. A second EPRI was performed on the following day. Autoradiography was performed after the second EPRI. After imaging, the tumor sections were evaluated by histological analysis and the amount of reducing substances in the tumor was measured. BSO treatment and X-ray irradiation significantly decreased the rate of 3CP reduction in tumors. Redox maps of tumors obtained from EPRI can be compared with tissue sections of approximately the same cross section. BSO treatment reduced glutathione levels in tumors, whereas X-ray irradiation did not alter the levels of any of the reducing substances. Comparison of the redox map with the autoradiography of [18F]FDG revealed that regions with high reducing power in the tumor were active in glucose metabolism; however, this correlation disappeared after X-ray irradiation. These results suggest that the novel compact and portable EPRI device is suitable for multimodal imaging, which can be used to study tumor redox status and therapeutic efficacy in cancer, and for combined analysis with other imaging modalities.
• Application of copper (I) selective ligands for PET imaging of reactive oxygen species through metabolic trapping

  Tetsuro Tada, Yuki Mizuno, Yuki Shibata, Hironobu Yasui, Yuji Kuge

  Nuclear Medicine and Biology 108914 - 108914 2024年04月
• Intravenous Administration of Mesenchymal Stem Cell-Derived Exosome Alleviates Spinal Cord Injury by Regulating Neutrophil Extracellular Trap Formation through Exosomal miR-125a-3p.

  Yutaka Morishima, Masahito Kawabori, Kazuyoshi Yamazaki, Soichiro Takamiya, Sho Yamaguchi, Yo Nakahara, Hajime Senjo, Daigo Hashimoto, Sakiko Masuda, Yoichiro Fujioka, Yusuke Ohba, Yuki Mizuno, Yuji Kuge, Miki Fujimura

  International journal of molecular sciences 25 4 2024年02月18日 

  Spinal cord injury (SCI) leads to devastating sequelae, demanding effective treatments. Recent advancements have unveiled the role of neutrophil extracellular traps (NETs) produced by infiltrated neutrophils in exacerbating secondary inflammation after SCI, making it a potential target for treatment intervention. Previous research has established that intravenous administration of stem cell-derived exosomes can mitigate injuries. While stem cell-derived exosomes have demonstrated the ability to modulate microglial reactions and enhance blood-brain barrier integrity, their impact on neutrophil deactivation, especially in the context of NETs, remains poorly understood. This study aims to investigate the effects of intravenous administration of MSC-derived exosomes, with a specific focus on NET formation, and to elucidate the associated molecular mechanisms. Exosomes were isolated from the cell supernatants of amnion-derived mesenchymal stem cells using the ultracentrifugation method. Spinal cord injuries were induced in Sprague-Dawley rats (9 weeks old) using a clip injury model, and 100 μg of exosomes in 1 mL of PBS or PBS alone were intravenously administered 24 h post-injury. Motor function was assessed serially for up to 28 days following the injury. On Day 3 and Day 28, spinal cord specimens were analyzed to evaluate the extent of injury and the formation of NETs. Flow cytometry was employed to examine the formation of circulating neutrophil NETs. Exogenous miRNA was electroporated into neutrophil to evaluate the effect of inflammatory NET formation. Finally, the biodistribution of exosomes was assessed using 64Cu-labeled exosomes in animal positron emission tomography (PET). Rats treated with exosomes exhibited a substantial improvement in motor function recovery and a reduction in injury size. Notably, there was a significant decrease in neutrophil infiltration and NET formation within the spinal cord, as well as a reduction in neutrophils forming NETs in the circulation. In vitro investigations indicated that exosomes accumulated in the vicinity of the nuclei of activated neutrophils, and neutrophils electroporated with the miR-125a-3p mimic exhibited a significantly diminished NET formation, while miR-125a-3p inhibitor reversed the effect. PET studies revealed that, although the majority of the transplanted exosomes were sequestered in the liver and spleen, a notably high quantity of exosomes was detected in the damaged spinal cord when compared to normal rats. MSC-derived exosomes play a pivotal role in alleviating spinal cord injury, in part through the deactivation of NET formation via miR-125a-3p.
• Intracerebral Transplantation of Mesenchymal Stromal Cell Compounded with Recombinant Peptide Scaffold against Chronic Intracerebral Hemorrhage Model

  Soichiro Takamiya, Masahito Kawabori, Tsukasa Kitahashi, Kentaro Nakamura, Yuki Mizuno, Hironobu Yasui, Yuji Kuge, Aki Tanimori, Yasuyuki Takamatsu, Kohei Yuyama, Hideo Shichinohe, Miki Fujimura

  Stem Cells International 2022 1 - 10 2022年07月31日 

  Background. Due to the lack of effective therapies, stem cell transplantation is an anticipated treatment for chronic intracerebral hemorrhage (ICH), and higher cell survival and engraftment are considered to be the key for recovery. Mesenchymal stromal cells (MSCs) compounded with recombinant human collagen type I scaffolds (CellSaics) have a higher potential for cell survival and engraftment compared with solo-MSCs, and we investigated the validity of intracerebral transplantation of CellSaic in a chronic ICH model. Methods. Rat CellSaics (rCellSaics) were produced by rat bone marrow-derived MSC (rBMSCs). The secretion potential of neurotrophic factors and the cell proliferation rate were compared under oxygen-glucose deprivation (OGD) conditions. rCellSaics, rBMSCs, or saline were transplanted into the hollow cavity of a rat chronic ICH model. Functional and histological analyses were evaluated, and single-photon emission computed tomography for benzodiazepine receptors was performed to monitor sequential changes in neuronal integrity. Furthermore, human CellSaics (hCellSaics) were transplanted into a chronic ICH model in immunodeficient rats. Antibodies neutralizing brain-derived neurotrophic factor (BDNF) were used to elucidate its mode of action. Results. rCellSaics demonstrated a higher secretion potential of trophic factors and showed better cell proliferation in the OGD condition. Animals receiving rCellSaics displayed better neurological recovery, higher intracerebral BDNF, and better cell engraftment; they also showed a tendency for less brain atrophy and higher benzodiazepine receptor preservation. hCellSaics also promoted significant functional recovery, which was reversed by BDNF neutralization. Conclusion. Intracerebral transplantation of CellSaics enabled neurological recovery in a chronic ICH model and may be a good option for clinical application.
• Influence of Linker Molecules in Hexavalent RGD Peptides on Their Multivalent Interactions with Integrin αvβ3

  Yuki Mizuno, Kohta Kimura, Satoru Onoe, Miho Shukuri, Yuji Kuge, Hiromichi Akizawa

  Journal of Medicinal Chemistry 2021年11月03日 [査読有り]
  
• Renal Handling of ^99mTc-Labeled Antibody Fab Fragments with a Linkage Cleavable by Enzymes on Brush Border Membrane.

  Tomoya Uehara, Naoki Kanazawa, Chie Suzuki, Yuki Mizuno, Hiroyuki Suzuki, Hirofumi Hanaoka, Yasushi Arano

  Bioconjugate chemistry 31 11 2618 - 2627 2020年11月18日 [査読有り]
   

  The high and persistent renal radioactivity levels after injection of radiolabeled low-molecular-weight polypeptides constitute a significant problem for their diagnostic and therapeutic applications, especially when they are labeled with metallic radionuclides. To improve the renal radioactivity levels of technetium-99m (99mTc)-labeled Fab fragments, a mercaptoacetyltriglycine (MAG3)-based new bifunctional chelating agent with a cleavable glycyl-phenylalanyl-lysine (GFK) linkage, MAG3-GFK-suc-TFP, was designed, synthesized, and evaluated. 99mTc-labeled Fab was obtained by reacting MAG3-GFK-Fab conjugate with 99mTc-glucarate. The GFK linkage remained stable in plasma but was cleaved by enzymes on the renal brush border membrane. The comparative biodistribution studies with indium-111 (111In)-labeled Fab using SCN-CHX-A″-DTPA showed that while both radiolabeled Fabs exhibited similar elimination rates from the blood, [99mTc]Tc-MAG3-GFK-Fab registered much lower renal radioactivity levels from 30 min post-injection onward due to the release and subsequent urinary excretion of [99mTc]Tc-MAG3-Gly. However, [99mTc]Tc-MAG3-GFK-Fab showed an increase in the intestinal radioactivity levels with the time that was not observed with 111In-labeled Fab. The analysis of the intestinal contents suggested the redistribution of [99mTc]Tc-MAG3-Gly to the intestine. The retrospective comparison of [99mTc]Tc-MAG3-GFK-Fab with the radiolabeled Fabs so far prepared under the identical concept suggested that some portion of [99mTc]Tc-MAG3-Gly was generated after the coated vesicle formation and they were excreted into the blood, and subsequently redistributed in the intestine via hepatobiliary excretion. In conclusion, MAG3-GFK-suc-TFP provided 99mTc-labeled Fabs that exhibit low renal radioactivity shortly after injection by the post-labeling procedure. The present study indicated that, contrary to our earlier proposal, the generation of the radiometabolites would proceed not only during the internalization process of the parental antibody fragments but also after coated vesicle formation. This study also showed that the intracellular behaviors of radiometabolites played crucial roles in the elimination rates and the routes of the radioactivity from the kidney.
• Aryl isocyanide derivative for one-pot synthesis of purification-free ^99mTc-labeled hexavalent targeting probe

  Yuki Mizuno, Nagiho Komatsu, Tomoya Uehara, Yuka Shimoda, Kohta Kimura, Yasushi Arano, Hiromichi Akizawa

  Nuclear Medicine and Biology 86-87 30 - 36 2020年07月 [査読有り][通常論文]
  
• Manipulating Pharmacokinetics of Purification-Free ^99mTc-Labeled Bivalent Probes for In Vivo Imaging of Saturable Targets

  Tomoya Uehara, Ayaka Sensui, Shiori Ishioka, Yuki Mizuno, Shiori Takahashi, Hideaki Takemori, Hiroyuki Suzuki, Yasushi Arano

  Molecular Pharmaceutics 17 5 1621 - 1628 2020年05月04日 [査読有り][通常論文]
   

  The accumulation of 99mTc-labeled probes targeting saturable systems of the body is hindered by the presence of a large excess of unlabeled ligands needed to ensure high radiochemical yields in a short reaction time. To address the issue, we recently reported a novel concept of a metal-coordination-mediated synthesis of a bivalent 99mTc-labeled probe from a monovalent ligand using d-penicillamine (Pen) as a chelating molecule and c(RGDfK) as a model targeting device. The Pen-conjugated c(RGDfK) via a hexanoate linkage (Pen-Hx-c(RGDfK)) provided a bivalent [99mTc]Tc-[(Pen-Hx-c(RGDfK))2 that possessed much higher integrin αvβ3 binding affinity than Pen-Hx-c(RGDfK) and visualized a murine tumor without purification. However, high radioactivity levels were observed in the abdominal regions, which necessitated improved pharmacokinetics of the probes for practical applications. In this study, a pharmacokinetic (PK) modifier was introduced to manipulate the pharmacokinetics of the 99mTc-Pen2-based bivalent probe. The Hx linkage in Pen-Hx-c(RGDfK) was replaced with acetyl-d-serine-d-serine-glycine (Ac-ssG) or hexanoyl-d-serine-d-serine-d-serine (Hx-sss) to prepare Pen-Ac-ssG-c(RGDfK) or Pen-Hx-sss-c(RGDfK). Pen-Ac-ssG-c(RGDfK) impaired the complexation ability of Pen-Hx-c(RGDfK), and a monovalent 99mTc-labeled compound was generated at low ligand concentration. However, Pen-Hx-sss-c(RGDfK) provided the objective bivalent 99mTc-labeled probe in high radiochemical yields at a concentration similar to that of Pen-Hx-c(RGDfK). [99mTc]Tc-[Pen-Hx-sss-c(RGDfK)]2 also possessed stability and integrin αvβ3 binding affinity similar to those of [99mTc]Tc-[Pen-Hx-c(RGDfK)]2. As a result, [99mTc]Tc-[Pen-Hx-sss-c(RGDfK)]2 exhibited tumor and abdominal radioactivity levels similar to and significantly lower than those of [99mTc]Tc-[Pen-Hx-c(RGDfK)]2. These findings indicate the incorporation of a tripeptide PK modifier to Pen-Hx-c(RGDfK) preserved the complexation ability and improved the pharmacokinetics of the resulting 99mTc-labeled bivalent probe without impairing the targeting ability. Thus, the [Pen-Hx-(PK modifier)-(targeting device)] would constitute a basic formulation for preparing the 99mTc-Pen2-based bivalent probes for imaging saturable targets of the body.
• The synthesis of a ^99mTc-labeled tetravalent targeting probe upon isonitrile coordination to ^99mTc^I for enhanced target uptake in saturable systems

  Yuki Mizuno, Tomoya Uehara, Chun-wei Jen, Hiromichi Akizawa, Yasushi Arano

  RSC Advances 9 45 26126 - 26135 2019年 [査読有り][通常論文]
   

  The difference in 2-proton's acidity between L_β and L_G led to dramatically different results of their reactions with [^99mTc][Tc(CO)₃(OH₂)₃]⁺.

• Coordination-Mediated Synthesis of ⁶⁷Ga-Labeled Purification-Free Trivalent Probes for in Vivo Imaging of Saturable Systems

  Holis A. Holik, Tomoya Uehara, Soki Nemoto, Takemi Rokugawa, Yuumi Tomizawa, Ayako Sakuma, Yuki Mizuno, Hiroyuki Suzuki, Yasushi Arano

  Bioconjugate Chemistry 29 9 2909 - 2919 2018年09月19日 [査読有り][通常論文]
  
• Coordination-Mediated Synthesis of Purification-Free Bivalent ^99mTc-Labeled Probes for in Vivo Imaging of Saturable System

  Yuichiro Taira, Tomoya Uehara, Masao Tsuchiya, Hideaki Takemori, Yuki Mizuno, Shiori Takahashi, Hiroyuki Suzuki, Hirofumi Hanaoka, Hiromichi Akizawa, Yasushi Arano

  Bioconjugate Chemistry 29 2 459 - 466 2018年02月21日 [査読有り][通常論文]
  
• Purification-Free Method for Preparing Technetium-99m-Labeled Multivalent Probes for Enhanced in Vivo Imaging of Saturable Systems

  Yuki Mizuno, Tomoya Uehara, Hirofumi Hanaoka, Yota Endo, Chun-Wei Jen, Yasushi Arano

  Journal of Medicinal Chemistry 59 7 3331 - 3339 2016年04月14日 [査読有り]
   

  Metallic radionuclides provide target-specific radiolabeled probes for molecular imaging in radiochemical yields sufficient for administration to subjects without purification. However, unlabeled ligands in the injectate can compete for targeted molecules with radiolabeled probes, which eventually necessitates postlabeling purification. Herein we describe a "1 to 3" design to circumvent the issue by taking advantage of inherent coordination properties of technetium-99m ((99m)Tc). A monovalent RGD ligand possessing an isonitrile as a coordinating moiety (CN-RGD) was reacted with [(99m)Tc(CO)3(OH2)3](+) to prepare [(99m)Tc(CO)3(CN-RGD)3](+) in over 95% radiochemical yields. This complex exhibited higher integrin αvβ3 binding affinity than its unlabeled monovalent ligand, primarily due to its multivalency. This compound visualized a murine tumor without removing unlabeled ligands, while a (99m)Tc-labeled monovalent probe derived from a monovalent ligand could not. The metal coordination-mediated synthesis of radiolabeled multivalent probes thereby can be a useful approach for preparing ready-to-use target-specific probes labeled with (99m)Tc and other metallic radionuclides of interest.

MISC

• ⁶⁸Ge/⁶⁸Gaジェネレータの長期間にわたる放射線管理上の安全性評価

  富田 翔, 東川 桂, 水野 雄貴, 多田 哲朗, 田沢 周作, 久下 裕司 RADIOISOTOPES 71 (1) 1 -8 2022年03月15日 [査読有り]
  
• ⁶⁸Ge/⁶⁸Ga ジェネレータの長期間の品質検査

  富田 翔, 東川 桂, 上野 悟史, 水野 雄貴, 田沢 周作, 久下 裕司 核医学 58 (1) 47 -58 2021年06月 [査読有り][通常論文]
  
• 核医学における‘Theranostics’

  水野 雄貴, 秋澤 宏行 ぶんせき (11) 505 -509 2019年11月 [査読有り][招待有り]
  
• Synthesis and evaluation of a ^99mTc-labeled hexavalent targeting probe from a monovalent ligand for in vivo imaging of saturable systems

  Y. Mizuno, N. Komatsu, T. Uehara, H. Akizawa, Y. Arano Nuclear Medicine and Biology 72-73 S3 -S3 2019年07月 [査読有り][通常論文]
  
• Design of a Trivalent Tc-99m-Probe for High Avidity Receptor Targeting and Enhanced Target Uptake

  Mizuno Yuki, Jen Chun-wei, Hanaoka Hirofumi, Uehara Tomoya, Arano Yasushi JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS 58 S119 2015年05月 [査読有り][通常論文]
  
• 錯形成により多価効果を発揮する新たな^99mTc標識薬剤の設計

  水野 雄貴, 任 鈞緯, 上原 知也, 花岡 宏史, 荒野 泰 日本分子イメージング学会機関紙 8 (1) 64 -65 2014年 [査読有り][招待有り]
  

講演・口頭発表等

• 複数のintegrin αvβ3と同時結合可能な多価cRGDペプチドの開発と多様な放射性同位元素で標識可能な構造への展開  [通常講演]

  水野雄貴, 林龍昕, 尾江悟, 秋澤宏行, 久下裕司

  第6回日本核医学会分科会放射性薬品科学研究会／第22回放射性医薬品・画像診断薬研究会 2023年09月 口頭発表（一般）
• 複数のintegrin αvβ3と同時結合可能な多価cRGDの化学構造：複数の細胞株を用いた検討

  水野雄貴, 林龍昕, 尾江悟, 秋澤宏行, 久下裕司

  バイオメディカル分析科学シンポジウム 2023年07月 口頭発表（一般）
• 18F-FDG PET/MRI によるマウス網膜変性疾患モデルの評価

  松元慎吾, 須藤志保, 安井博宣, 水野雄貴, 久下裕司, 山田健一, 平田拓

  第17回分子イメージング学会総会・学術集会 2023年06月 ポスター発表
• Synthesis of [64Cu]Cu+ complex for redox imaging and evaluation of its reactivity with reactive oxygen species  [通常講演]

  Tetsuro Tada, Yuki Mizuno, Yuki Shibata, Hironobu Yasui, Yuji Kuge

  The 25th International Symposium of Radiopharmaceutical Sciences (iSRS 2023) 2023年05月 ポスター発表
• The synthesis and evaluation of [68Ga]Ga-HBED-CC-TfRB1G3 for TfR1 imaging  [通常講演]

  Longxin Lin, Yuki Mizuno, Yuki Shibata, Hironobu Yasui, Yuji Kuge

  The 25th International Symposium of Radiopharmaceutical Sciences (iSRS 2023) 2023年05月 ポスター発表
• Cystine-dense peptide TfRB1G3 のTfR1への親和性評価と68Ga標識に向けたHBED-CC結合体の合成  [通常講演]

  林 龍昕, 水野 雄貴, 久下 裕司, 柴田 悠貴, 安井 博宣

  日本薬学会第143年会 2023年03月 ポスター発表
• 多価RGDペプチドが複数のintegrin αvβ3と同時結合するために重要な化学構造の探索  [通常講演]

  水野 雄貴, 尾江 悟, 宿里 充穗, 秋澤 宏行, 久下 裕司

  日本薬学会第143年会 2023年03月 ポスター発表
• 導入したRGDペプチドの数がアルブミン二量体の体内動態挙動に及ぼす影響  [通常講演]

  杉田茉央, 尾江悟, 大井一生, 熊川由利香, 金子瑞希, 水野雄貴, 宿里充穗, 秋澤宏行

  日本薬学会第143年会 2023年03月 ポスター発表
• Glyoxalase I標的イメージングプローブの開発研究: 放射性ヨウ素導入グルタチオン類似体のジエステルの細胞内代謝挙動に関する検討  [通常講演]

  大庭 栞, 尾江 悟, 高堂 歌音, 水野 雄貴, 宿里 充穗, 秋澤 宏行

  日本薬学会第143年会 2023年03月 ポスター発表
• 視覚的効果を付与したRI-web教材の開発  [通常講演]

  阿保憲史, 水野雄貴, 吉井勇治, 久下裕司

  第4回日本保健物理学会・日本放射線安全管理学会合同大会
• 多目的用途に使用可能な放射線測定校正用治具の開発  [通常講演]

  阿保憲史, 吉井勇治, 水野雄貴, 久下裕司

  第4回日本保健物理学会・日本放射線安全管理学会合同大会
• β線被ばくに対する放射線教育を支援する教材の開発  [通常講演]

  吉井勇治, 阿保憲史, 水野雄貴, 久下裕司

  第4回日本保健物理学会・日本放射線安全管理学会合同大会
• Cystine-dense peptideを母体としたTfR1イメージング薬剤開発に向けた基礎的検討  [通常講演]

  林 龍昕, 水野 雄貴, 柴田 悠貴, 安井 博宣, 久下 裕司

  第8回 北大・部局横断シンポジウム 2022年10月 ポスター発表
• レドックスイメージングを目的とした[64Cu][CuI(BCS)2]+の合成とROSとの反応性評価  [通常講演]

  多田哲朗, 水野雄貴, 柴田悠貴, 安井博宣, 久下裕司

  第5回日本核医学会分科会 放射性薬品科学研究会 2022年09月 口頭発表（一般）
• Development of 99mTc-labeled hexavalent c(RGDfK) peptide with optimized linker structure for in vivo imaging of integrin αvβ3.  [通常講演]

  Yuki Mizuno, Kohta Kimura, Satoru Onoe, Miho Shukuri, Yuji Kuge, Hiromichi Akizawa

  The Fourth International Symposium on Technetium and Other Radiometals in Chemistry and Medicine 2022年09月 口頭発表（一般）
• 自動合成装置で製造した68Ga-PSMA-11 注射液に含まれる不純物  [通常講演]

  菊池 康子, 水野 雄貴, 多田 哲朗, 富田 翔, 田沢 周作, 鷲野 弘明, 菅原 雄一郎, 久下 裕司

  第62回⽇本核医学会学術総会 2022年09月 口頭発表（一般）
• ROSイメージングを目的とした[64Cu]Cu+錯体の合成と評価：配位子構造が錯体の安定性に与える影響  [通常講演]

  多田 哲朗, 水野 雄貴, 柴田 悠貴, 安井 博宣, 久下 裕司

  第62回日本核医学会学術総会 2022年09月 口頭発表（一般）
• トランスポーター高発現細胞を用いたチミジンホスホリラーゼ標的放射性プローブ[123I]IIMUの取り込み機構に関する検討

  長谷川舞衣, 宿里充穗, 尾江 悟, 水野雄貴, 久下裕司, 秋澤 宏行

  日本薬学会第142年会 2022年03月 ポスター発表
• トランスフェリン受容体認識直鎖ペプチドを母体とした68Ga標識プローブの合成と評価

  水野 雄貴, 三浦春香, 安井博宣, 柴田悠貴, 大久保直登, 前原経, 武田宏司, 大西俊介, 久下裕司

  日本薬学会第142年会 2022年03月 ポスター発表
• ROSイメージングを目的としたメタボリックトラップ型PETプローブの開発：CuI-BCA錯体の利用

  多田哲朗, 水野雄貴, 柴田悠貴, 安井博宣, 久下裕司

  日本薬学会第142年会 2022年03月 ポスター発表
• ⁶⁸Ga標識反応の収率に影響を及ぼす鉄濃度︓⁶⁸Ge/⁶⁸Gaジェネレータ溶出液中に含まれる鉄濃度との⽐較  [通常講演]

  多田 哲朗, 富田 翔, 水野 雄貴, 田沢 周作, 久下 裕司

  第61回⽇本核医学会学術総会 2021年11月 口頭発表（一般）
• ROSイメージングを目的としたメタボリックトラップ型PETプローブの開発：Cu^I-イソニトリル錯体の利用  [通常講演]

  多田 哲朗, 水野 雄貴, 柴田 悠貴, 安井 博宣, 久下 裕司

  第7回北大・部局横断シンポジウム 2021年10月 ポスター発表
• ⁶⁸Ga標識トランスフェリン受容体認識ペプチドによるがんイメージングの検討  [通常講演]

  三浦 春香, 水野 雄貴, 髙橋 春香, 大久保 直登, 前原 経, 久下 裕司, 武田 宏司, 大西 俊介

  第7回北大・部局横断シンポジウム 2021年10月 ポスター発表
• 2価環状RGDペプチドのスペーサ構造がintegrin α_vβ₃陽性細胞との相互作用に与える影響  [通常講演]

  水野雄貴, 宮本莉里, 尾江悟, 宿里充穂, 久下裕司, 秋澤宏行

  第4回日本核医学会分科会 放射性薬品科学研究会 2021年09月 口頭発表（一般）
• 非アルコール性脂肪肝炎におけるチミジンホスホリラーゼの機能解析  [通常講演]

  髙橋春香, 前原経, 水野雄貴, 三浦春香, 上原里穂, 大久保直登, 須田剛生, 森川賢一, 坂本直哉, 久下裕司, 武田宏司, 大西俊介

  第34回北海道薬物作用談話会 2021年09月 口頭発表（一般）
• 多価RGDのリンカー構造がintegrin α_vβ₃陽性細胞との相互作用に及ぼす 影響  [通常講演]

  水野 雄貴, 木村 倖大, 尾江 悟, 宿里 充穗, 久下 裕司, 秋澤 宏行

  日本薬学会 第141年会 2021年03月 口頭発表（一般）
• Synthesis and evaluation of a ^99mTc-labeled hexavalent targeting probe from a monovalent ligand for in vivo imaging of saturable systems  [通常講演]

  水野 雄貴

  The 3rd International Symposium on Technetium and Other Radiometals in Chemistry and Medicine 2018年09月 口頭発表（一般）
• In-situ preparation of trivalent ^99mTc/^186/188Re-labeled compounds from monovalent ligand for ready-to-use theranostic radiopharmaceuticals: Factors affecting radiochemical yields of isonitrile-based trivalent ^99mTc/^186/188Re-labeled compounds.  [通常講演]

  Yuki Mizuno, Chun-Wei Jen, Tomoya Uehara, Yasushi Arano

  THE INTERNATIONAL CHEMICAL CONGRESS OF PACHIFIC BASIN SOCIETIES 2015 2015年12月 ポスター発表
• Factors affecting radiochemical yields of isonitrile-based ^99mTc-labeled trivalent probes for molecular imaging.  [通常講演]

  Yuki Mizuno, Chun-Wei Jen, Tomoya Uehara, Yasushi Arano

  Ninth Japan-China Joint Seminar on Radiopharmaceutical Chemistry 2015年11月 口頭発表（一般）
• Design of a Trivalent ^99mTc-Probe for High Avidity Receptor Targeting and Enhanced Target Uptake.  [通常講演]

  Yuki Mizuno, Chun-Wei Jen, Hirofumi Hanaoka, Tomoya Uehara, Yasushi Arano

  The 21th International Symposium on Radiopharmaceutical Sciences 2015年05月 ポスター発表

所属学協会

• 日本分子イメージング学会   日本核医学会   日本薬学会